Ionis Pharmaceuticals Q4 Earnings Call Highlights

Core Insights - Ionis Pharmaceuticals has successfully executed its first two independent commercial launches, DAWNZERA and TRYNGOLZA, marking a significant year for the company [3] Product Launches - DAWNZERA, approved in August as a prophylactic treatment for hereditary angioedema (HAE), is the first RNA-targeted medicine for HAE, with a peak sales potential exceeding $500 million [1] - TRYNGOLZA, the first FDA-approved treatment for familial chylomicronemia syndrome (FCS), generated fourth-quarter net product sales of $50 million, a 56% increase sequentially, and full-year revenue of $108 million [2][6] Financial Performance - Ionis reported 2025 revenue of $944 million, a 34% year-over-year increase, with 46% from commercial products and 54% from R&D collaborations [12] - The company provided 2026 revenue guidance of $800 million to $825 million, reflecting a one-time $280 million license fee in 2025, indicating approximately 20% underlying growth [4][14] Pipeline Developments - Olezarsen for severe hypertriglyceridemia (sHTG) showed up to a 72% triglyceride reduction and an 85% reduction in acute pancreatitis events, with a supplemental NDA submitted and priority review requested [5][8] - Zilganersen for Alexander disease is anticipated to receive approval in the second half of 2026, with peak revenue guidance exceeding $100 million [9] Commercial Strategy - The company emphasized strong early adoption for DAWNZERA, with a 100% conversion to paid therapy from the free trial program [1] - Management noted that approximately 75% of TRYNGOLZA prescriptions came from specialists, indicating a targeted approach to market penetration [2] Future Outlook - Ionis aims for cash-flow breakeven by 2028, with a projected non-GAAP operating loss of $500 million to $550 million for 2026 [20][21] - The company expects a meaningful decline in TRYNGOLZA revenue during 2026 ahead of the sHTG launch, followed by growth if approval occurs [16]